Net Income

Following a landmark FDA approval and strong earnings, Axsome must convince investors its momentum can translate into long-term profitability and leadership.

A new biotech emerges with a promising, late-stage gene therapy for Sanfilippo syndrome, offering a potential lifeline for children with no other options.

With profits up and a new CEO, TVA is pouring billions into new generation, betting on advanced nuclear power to meet soaring demand from data centers.

Atkore's Q2 revenue rose 4.2%, but a $136.5M antitrust settlement drove a major net loss. The company divests assets to focus on its electrical core.

Operational failures at a key new mine pushed Peabody to a Q1 loss, overshadowing strong thermal coal profits fueled by geopolitical conflict.

The utility giant posted strong first-quarter earnings, driven by surging industrial demand, and reaffirmed its outlook amid a historic investment plan.

The ticket marketplace saw revenue fall year-over-year, but a surge in cash flow and sequential growth offers a potential path to recovery.

A new drug, CS-1103, earns FDA Fast Track to combat fentanyl overdoses by binding and removing the opioid, a potential game-changer over naloxone.

Enlight Renewable Energy posts strong Q1 results, with underlying profits surging 76% despite a misleading net income dip, and reaffirms its 2026 outlook.

A new report reveals U.S. firms lead in security spending intent but lag in AI deployment, creating a dangerous gap between belief and reality.

A new geological report confirms gold potential at Treasure Canyon, but for a company with no revenue, the path to riches is paved with high risk.

California's LBC Capital expands its $1B bridge lending platform nationwide, betting its conservative underwriting can capture a growing private credit market.

Meren Energy's upcoming Q1 2026 results will be scrutinized for its performance in Africa's deepwater projects amidst soaring oil prices and strategic shifts.

A top European fertility network is rolling out AI to select embryos, promising higher success rates but sparking debate on the future of data-driven parenthood.

Anomali's new platform uses 'agentic AI' to automate cyber defense decisions, promising a 300x speed boost. But can it deliver on its ambitious vision?

A decade-high snowfall fueled a record first quarter for the work truck giant, which is now raising its full-year forecast despite economic headwinds.

Beyond its first blockbuster, CRISPR Therapeutics reveals a deep pipeline for autoimmune and liver diseases, backed by a strong Q1 balance sheet.

Aero Energy acquires Urano and Pegasus, rebranding as Manhattan Uranium Discovery Corp. to create a diversified powerhouse in a booming uranium market.

The trust advances major Toronto developments and improves its debt position, signaling a long-term strategy amid a challenging real estate market.

The biotech's blockbuster Nasdaq debut provides crucial capital for its promising pipeline, offering new hope for patients with severe bleeding conditions.